About: Guillaume Cartron

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Guillaume Cartron Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

researcher

Attributes	Values
rdf:type	Item
description	forskare (sv) researcher (en) 연구원 (ko) ricercatore (it) গবেষক (bn) 研究者 (ja) ഗവേഷകൻ (ml) investigador (es) araştırmacı (tr) wetenschapper (nl) дослідник (uk) वैज्ञानिक (hi) изилдөөчү (ky) 研究者 (zh) հետազոտող (hy) hulumtues (sq)
rdfs:label	Guillaume Cartron (en) Guillaume Cartron (es) Guillaume Cartron (it) Guillaume Cartron (nl) Guillaume Cartron (sl) Guillaume Cartron (ast)
skos:prefLabel	Guillaume Cartron (en) Guillaume Cartron (es) Guillaume Cartron (it) Guillaume Cartron (nl) Guillaume Cartron (sl) Guillaume Cartron (ast)
name	Guillaume Cartron (en) Guillaume Cartron (es) Guillaume Cartron (it) Guillaume Cartron (nl) Guillaume Cartron (sl) Guillaume Cartron (ast)
given name	wds:Q38803376-CC8FACD2-F46B-4C94-98ED-C149665DB6FA
given name	Guillaume
instance of	wds:Q38803376-E89B9587-3033-443B-8516-A16170D70287
instance of	Homo sapiens
occupation	wds:Q38803376-86AC4D3F-76D9-491C-8EDC-DE66A61CFACA
sex or gender	wds:Q38803376-98A34B1D-C356-4160-9FFC-351FF0A7A1C0
ISNI	wds:Q38803376-39C95F40-D7D1-4577-83E6-B3C5CCC621CB
VIAF ID	wds:Q38803376-EBC0E898-BDAA-410E-B120-2BFA79D9A4BB
Library of Congress authority ID	wds:Q38803376-CD0EB0A1-3A80-4C24-9FBF-D1A4CDDF4E5E
IdRef ID	wds:Q38803376-B844ACDF-EDB9-437D-B12B-25B3CD001796
date of birth	wds:Q38803376-AE9B4CAF-54F3-4DE5-97EA-3362C636056B
family name	wds:Q38803376-5E3681E5-7E1C-4182-966D-5452C28C5C40
WorldCat Identities ID (superseded)	wds:Q38803376-EEFEAE6E-1950-44BA-839F-9E2705E933D6
National Library of Israel J9U ID	wds:Q38803376-C75633CD-AA23-416E-B894-F89360E5D932
VIAF ID	http://viaf.org/viaf/69264965
Library of Congress authority ID	http://id.loc.gov/authorities/names/n2014182533
IdRef ID	http://www.idref.fr/075137119/id
occupation	researcher
sex or gender	male
ISNI	0000000002568178
VIAF ID	69264965
Library of Congress authority ID	n2014182533
IdRef ID	075137119
date of birth	1966-01-01 00:00:00Z (xsd:dateTime)
family name	Cartron
WorldCat Identities ID (superseded)	lccn-n2014182533
National Library of Israel J9U ID	987007319801605171
Springer Nature person ID	wds:Q38803376-74D603D2-64F3-4407-AE47-05896150A805
ORCID iD	wds:Q38803376-E05C03BB-7840-4EA4-ACB1-665609B7BD70
Dimensions author ID	wds:Q38803376-C1D23AF8-9C53-45BD-86BE-B92AD027133D
ORCID iD	https://orcid.org/0000-0003-0659-9635
Springer Nature person ID	01003610157.21
ORCID iD	0000-0003-0659-9635
Dimensions author ID	01003610157.21
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q38803376
is author of	Evaluation of a peptide ELISA for the detection of rituximab in serum. Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. EZH2 in normal hematopoiesis and hematological malignancies Localized low-dose radiotherapy for follicular lymphoma: history, clinical results, mechanisms of action, and future outlooks Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. From the bench to the bedside: ways to improve rituximab efficacy. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines Clinical radioimmunotherapy--the role of radiobiology. Dose-response relationship and pharmacogenetics of anti-RhD monoclonal antibodies Pharmacokinetics of rituximab and its clinical use: thought for the best use? Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. DNA repair in diffuse large B-cell lymphoma: a molecular portrait Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study Circulating miRNA-125b is a potential biomarker predicting response to rituximab in rheumatoid arthritis Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study. Human Leukemic Cells performing Oxidative Phosphorylation (OXPHOS) Generate an Antioxidant Response Independently of Reactive Oxygen species (ROS) Production Identification of Anti-tumor Cells Carrying Natural Killer (NK) Cell Antigens in Patients With Hematological Cancers Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment. Obinutuzumab in hematologic malignancies: lessons learned to date

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 195 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software